The fight against HIV continues
There are 52 experimental HIV drugs in the portfolios of American pharmaceutical companies
American biotech companies do not give up in the face of HIV – currently 52 medicines and vaccines designed for the prevention and treatment of a viral disease are at the stage of development and registration. This is evidenced by the data of a report prepared by the Association of Pharmaceutical Developers and Manufacturers of the USA (PhRMA) in collaboration with the AIDS Institute (More Than 50 Medicines and Vaccines in Development for HIV Infection, Treatment and Prevention).
Among these 52 medicines: 32 antiretroviral and antiviral drugs, 16 vaccines and 4 cell therapies, including a promising agent that prevents the virus from penetrating the cell membrane of healthy cells.
Thanks to the successful work on new medicines over the past three decades, HIV mortality/AIDS has decreased by 88%. Currently, the projected life expectancy of 20-year-old patients who started ARV therapy in 2013 is 10 years longer than this indicator for those who started therapy in 1996. The average predicted life expectancy for young HIV-positive patients was, according to scientists, 78 years.
According to scientists, the improvement in the predicted life expectancy has become possible only thanks to the transition to less toxic drug combinations and the emergence of therapies for drug-resistant HIV strains. All this led to an increase in the patient's adherence to treatment, and consequently, to better survival rates.
Portal "Eternal youth" http://vechnayamolodost.ru
03.07.2017